{
  "meta": {
    "publisher": "Mass Tort Marketing Agency",
    "dataset": "Cost Per Signed Retainer (CPR) Benchmark",
    "release": "2026-q1",
    "quarter": "Q1 2026",
    "temporalCoverage": "2026-01-01/2026-03-31",
    "dataAsOf": "2026-03-31",
    "published": "2026-04-24",
    "lastReviewed": "2026-06-10",
    "methodologyVersion": "1.0",
    "methodologyUrl": "https://www.masstortmarketingagency.com/benchmarks/methodology",
    "canonicalUrl": "https://www.masstortmarketingagency.com/benchmarks/oxbryta",
    "verification": {
      "status": "unverified",
      "reviewer": null,
      "statement": "No third party has reviewed this methodology or the underlying data. Mass Tort Marketing Agency sells the leads these figures price."
    },
    "vendorDisclosure": "Mass Tort Marketing Agency sells the mass tort leads these figures price. The panel is the agency's own client base and the underlying performance data is self-reported by those firms.",
    "sourcesDisclosure": "Benchmark ranges are drawn from the panel performance data cross-referenced against published industry surveys and practitioner-disclosed benchmarks. Those sources are not named in the published methodology, and how they enter the calculation is not specified.",
    "license": {
      "name": "CC BY 4.0",
      "url": "https://creativecommons.org/licenses/by/4.0/",
      "attribution": "Mass Tort Marketing Agency CPR Benchmark, https://www.masstortmarketingagency.com/benchmarks/"
    },
    "nullConvention": "A null value is never a zero and never an estimate. Every null is paired with an adjacent *Reason field stating why the value is unavailable.",
    "snapshotUrl": "https://www.masstortmarketingagency.com/benchmarks/data/2026-q1.json"
  },
  "tort": {
    "slug": "oxbryta",
    "name": "Oxbryta (sickle cell disease)",
    "status": "Active",
    "cpr": {
      "low": 5800,
      "median": null,
      "medianUnavailableReason": "Per-tort medians are not published. The dataset carries the interquartile low and high bounds for each tort; only the national median is published as a point value.",
      "high": 8400,
      "currency": "USD"
    },
    "signedRatePct": {
      "low": 6,
      "high": 9
    },
    "qualificationTier": "Very High",
    "sampleSize": null,
    "sampleSizeUnavailableReason": "Per-tort sample sizes are not broken out in the published dataset. The panel total (140 firms, $180M of annual mass tort lead spend across 16 active tort categories) is published at the panel level only, so the number of firms and the spend basis behind any single row cannot be stated.",
    "confidenceInterval": null,
    "confidenceIntervalUnavailableReason": "Not computable from the published dataset. Benchmarks are published as trimmed interquartile ranges, and the per-observation values a confidence interval requires are not retained in the published figures.",
    "falloffPct": null,
    "falloffUnavailableReason": "Not published for this tort. The source dataset does not state a numeric falloff range for Oxbryta.",
    "falloffNote": null,
    "rowUpdated": "2026-04-24",
    "rowUpdatedNote": "Rows are refreshed as a complete set each release, so every row carries the release publication date rather than an independent per-row date.",
    "qualificationCriteria": "Documented Oxbryta (voxelotor) use plus a documented vaso-occlusive crisis hospitalization or wrongful death.",
    "statusAndAcquisition": "Active post-withdrawal tort — Pfizer voluntarily withdrew voxelotor in September 2024 following safety concerns around vaso-occlusive crises and mortality signals. Signed rates reflect both the narrow claimant pool and the demographic concentration of sickle cell disease patients. Paid-digital acquisition alone is inefficient here; firms building relationships with sickle cell disease advocacy organizations and hematology practices in the Southeast and mid-Atlantic typically operate at $4,000-$5,500 CPR, well below paid-digital-only firms.",
    "relatedTorts": [
      "olympus-scope",
      "pfas-personal-injury",
      "ozempic"
    ],
    "canonicalUrl": "https://www.masstortmarketingagency.com/benchmarks/oxbryta",
    "quarter": "Q1 2026"
  },
  "series": {
    "low": [
      {
        "release": "2024-q4",
        "label": "Q4 2024",
        "dataAsOf": "2024-12-31",
        "value": null,
        "valueReason": "No per-tort breakdown for Q4 2024 is held in the dataset. Only the national median is held for that quarter, which is why the per-tort trend series begins at Q1 2026."
      },
      {
        "release": "2026-q1",
        "label": "Q1 2026",
        "dataAsOf": "2026-03-31",
        "value": 5800,
        "valueReason": null
      }
    ],
    "high": [
      {
        "release": "2024-q4",
        "label": "Q4 2024",
        "dataAsOf": "2024-12-31",
        "value": null,
        "valueReason": "No per-tort breakdown for Q4 2024 is held in the dataset. Only the national median is held for that quarter, which is why the per-tort trend series begins at Q1 2026."
      },
      {
        "release": "2026-q1",
        "label": "Q1 2026",
        "dataAsOf": "2026-03-31",
        "value": 8400,
        "valueReason": null
      }
    ]
  },
  "annotations": []
}